Pietragalla Antonella, Ciccarone Francesca, Nero Camilla, Scambia Giovanni, Lorusso Domenica, Daniele Gennaro
Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Catholic University of the Sacred Heart, 00168 Rome, Italy.
Explor Target Antitumor Ther. 2020;1(3):171-182. doi: 10.37349/etat.2020.00011. Epub 2020 Jun 29.
Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.
聚（ADP-核糖）聚合酶抑制剂（PARP-I）是在复发性卵巢癌（OC）和晚期治疗中研究的最具吸引力和前景的一类生物制剂。这类新药的出现改变了OC的临床管理，为这种侵袭性癌症带来了前所未有的进展。目前有三种口服PARP-I可用：奥拉帕利、尼拉帕利和鲁卡帕利。另外两种正在积极进行临床探索：维利帕利和他拉唑帕利。在此，作者报告了PARP-I的临床数据，特别强调了支持监管机构批准PARP-I用于OC患者的II期和III期试验。
